- 15 May 2026 19:24:02
- Source: Sharecast
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE")
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION
FOR IMMEDIATE RELEASE
15 May 2026
No intention to make an offer for AMS
Further to the announcement on 18 April 2026 by Advanced Medical Solutions Group plc ("AMS") that funds affiliated with TA Associates (UK), LLP (together, "TA") were considering a possible offer for the entire issued and to be issued share capital of AMS, TA today confirms that it does not intend to make an offer for AMS.
TA is grateful for the engagement with the AMS Board and management team and would like to thank them for their time and consideration of this potential transaction.
This is a statement to which Rule 2.8 of the Code applies. Accordingly, TA and any person(s) acting in concert with it will, except with the consent of the Panel on Takeovers and Mergers (the "Takeover Panel"), be bound by the restrictions set out in Rule 2.8 of the Code. Under Note 2 on Rule 2.8 of the Code, TA, and any person(s) acting in concert with it, reserves the right to set the restrictions in Rule 2.8 of the Code aside in the following circumstances:
a) with the agreement of the board of Directors of AMS;
b) following the announcement of a firm intention to make an offer for AMS by, or on behalf of, a third party;
c) following the announcement by AMS of a Rule 9 waiver proposal (as described in Note 1 of the Notes on Dispensations from Rule 9 of the Code), or a reverse takeover (as defined by the Code); or
d) where the Takeover Panel has determined that there has been a material change in circumstances.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
